Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

FERN GAIL FRIED

Allopathic & Osteopathic Physicians Dermatology

NPI
1760422422
CMS profile
34021
Location
YARDLEY, PA

General Payments · PY2018–2024

$4,537.19

  • Reported across 99 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$765.42

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $765.42 14

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $180.91 4
Galderma Laboratories, L.P. $153.24 2
Dermavant Sciences, Inc. $125.00 1
Lilly USA, LLC $111.54 1
LEO Pharma Inc. $97.47 4
Incyte Corporation $76.53 1
REVANCE THERAPEUTICS, INC. $20.73 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $1,388.83 33
PY2019 $1,089.65 19
PY2020 $320.57 9
PY2021 $286.54 8
PY2022 $330.44 8
PY2023 $355.74 8
PY2024 $765.42 14

Payment records · PY2024 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $130.00 03/14/2024 Food and Beverage Undisputed 01/23/2026 1103755267 CMS
ABBVIE INC. $15.93 03/15/2024 Food and Beverage Undisputed 01/23/2026 1103755269 CMS
ABBVIE INC. $17.04 05/03/2024 Food and Beverage Undisputed 01/23/2026 1103755271 CMS
ABBVIE INC. $17.94 10/09/2024 Food and Beverage Undisputed 01/23/2026 1103755273 CMS
Dermavant Sciences, Inc. $125.00 05/22/2024 Food and Beverage Undisputed 01/23/2026 1127867662 CMS
Galderma Laboratories, L.P. $136.74 09/04/2024 Food and Beverage Undisputed 01/23/2026 1145297992 CMS
Galderma Laboratories, L.P. $16.50 09/04/2024 Food and Beverage Undisputed 01/23/2026 1145297994 CMS
Incyte Corporation $76.53 05/15/2024 Food and Beverage Undisputed 01/23/2026 1141270692 CMS
LEO Pharma Inc. $27.34 04/26/2024 Food and Beverage Undisputed 01/23/2026 1152630281 CMS
LEO Pharma Inc. $27.34 05/30/2024 Food and Beverage Undisputed 01/23/2026 1152630283 CMS
LEO Pharma Inc. $22.73 08/06/2024 Food and Beverage Undisputed 01/23/2026 1152630285 CMS
LEO Pharma Inc. $20.06 09/25/2024 Food and Beverage Undisputed 01/23/2026 1152630287 CMS
Lilly USA, LLC $111.54 11/07/2024 Food and Beverage Undisputed 01/23/2026 1134972967 CMS
REVANCE THERAPEUTICS, INC. $20.73 02/15/2024 Food and Beverage Undisputed 01/23/2026 1147918116 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.